Sabra Health Care REIT reported a net loss of $(0.61) per diluted common share for the second quarter of 2021. The company announced its intention to exit the Enlivant Joint Venture and provided full-year 2021 guidance. The company's Net Debt to Adjusted EBITDA ratio improved to 4.75x.
Net loss per diluted common share was $(0.61).
EBITDARM Coverage for Aggregate Acute/Post Acute and Other facilities reported 2.27x, which represents an increase of 0.36x over the second quarter of 2020 and an increase of 0.02x over the first quarter of 2021.
Collected 99.8% of forecasted rents from the beginning of the COVID-19 pandemic through July 2021.
The company issued 4.9 million shares of common stock under our at-the-market offering program (“ATM Program”) for net proceeds of $85.0 million.
Sabra expects the following amounts per diluted common share for the year ending December 31, 2021: Net loss: $(0.15) - $(0.13), FFO: $1.53 - $1.55, NFFO: $1.56 - $1.58, AFFO: $1.51 - $1.53, NAFFO: $1.53 - $1.55
Visualization of income flow from segment revenue to net income